Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd

View Full Paper
Ask AI
Bookmark
Share

Authors

RKRathan KumarLNLotus Neidemire-ColleyEGElizabeth A.R. Garfinkle

Discussion

Loading...

Member takes

Overview

BET inhibition reduces fibrosis and improves pulmonary function in bronchiolitis obliterans, highlighting its therapeutic potential in chronic gvhd.

Key Points

  • Bronchiolitis obliterans syndrome is a lethal complication of chronic gvhd, and BET inhibition can reduce fibrosis.
  • Treatment with BET inhibitors showed significant improvements in pulmonary function tests and reduced collagen deposition.
  • Analysis included single-cell RNA sequencing to identify macrophage polarization changes in response to BET inhibition.
  • Epigenetic readers play a critical role in managing inflammation and fibrosis pathways in bronchiolitis obliterans.

Cite This Study

Kumar et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6dchttps://doi.org/10.1182/blood-2025-5859
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis2025
  2. 2Abstract B012: Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)2025
  3. 3Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH)2025
  4. 4Discovery of the transcription factor ZNF683/hobit as a central regulator of pathogenic T cell proliferation in acute gvhd2025
  5. 5Taiwan consensus on pulmonary chronic graft‐versus‐host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation ( TBMT ) and Taiwan Society of Pulmonary and Critical Care Medicine ( TSPCCM )2025 · 1 citations